Drugs /

inbrx-109

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, INBRX-109 specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.

Clinical Trials

View Clinical Trials for inbrx-109

Inbrx-109 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating inbrx-109, 1 is phase 1 (1 open).

Malignant pleural mesothelioma, malignant solid tumor, and pancreatic adenocarcinoma are the most common diseases being investigated in inbrx-109 clinical trials [2].

Drug Details

Synonyms [2]:
inbrx109, inbrx 109, anti-dr5 agonistic monoclonal antibody inbrx-109
Drug Target(s) [2]:
TNFRSF10B
NCIT ID [1]:
C157062

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.